Health Catalyst Reduces Board Size to Five Directors
Health Catalyst announced actions to reduce the size of the Board. Dawn Smith and Duncan Gallagher stepped down from the Board, effective February 17 and John Kane will step down on April 1. These changes are in addition to the planned departure of Matt Kolb, who previously notified the Company that he will not seek reelection as a director at the 2026 Annual Meeting of Shareholders and will complete his board service immediately prior to the 2026 Annual Meeting. As a result of these changes, the size of the Board has been reduced at the effective time of each of the departures and will ultimately be set at five directors immediately prior to the 2026 Annual Meeting. Health Catalyst is grateful for the contributions and service of the departing directors. In addition, Spencer has been elected to serve as Chair of the Board. Matt Arens has been named Chair of the Nominating and Corporate Governance Committee, which now consists of Arens and Jill Hoggard Green; Julie Larson-Green will continue to serve as Chair of the Compensation Committee; and Mr. Kane will continue to serve as Chair of the Audit Committee until his departure. The Audit Committee now consists of Kane, Spencer, and Larson-Green.
Trade with 70% Backtested Accuracy
Analyst Views on HCAT
About HCAT
About the author
Health Catalyst Appoints New CEO Ben Albert Amid Board Restructuring
- Executive Transition: Health Catalyst announced that Ben Albert will become the new CEO effective February 12, which aims to expedite the succession planning for retiring CEO Dan Burton, highlighting the company's commitment to leadership stability.
- Board Restructuring: The company is reducing its board size ahead of the 2026 Annual Meeting, with the departure of three directors leading to a total of five members, which may impact governance structure and decision-making efficiency.
- Historical Context: Ben Albert joined Health Catalyst in 2025 during the acquisition of Upfront Healthcare Services and became president and COO in 2022, indicating the company's preference for internal promotion to maintain management continuity.
- Future Outlook: With Dan Burton planning to retire in 2026, Albert's appointment not only accelerates succession planning but may also bring new strategic directions to the company, enhancing its competitive edge in the market.
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
- New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
- Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
- Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
- Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
- New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
- Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
- Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
- Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
Health Catalyst to Attend Upcoming Investor Conferences
Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.
Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.
Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.
Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
Health Catalyst (HCAT) Q3 Earnings Review: Analyzing Key Metrics Against Expectations
Health Catalyst Financial Performance: For Q3 2025, Health Catalyst reported revenue of $76.32 million, unchanged from the previous year, with an EPS of $0.06, down from $0.07 a year ago.
Earnings Surprises: The company's revenue exceeded the Zacks Consensus Estimate by 1.66%, and it delivered a 20% EPS surprise compared to the consensus estimate of $0.05.
Investor Insights: Key metrics beyond headline numbers are crucial for understanding a company's performance and guiding investors' decisions regarding stock price projections.
Stock Recommendations: Zacks Investment Research highlighted five stocks with potential for significant growth, emphasizing opportunities in lesser-known stocks that have previously shown substantial returns.
Health Catalyst Appoints New CEO Ben Albert Amid Board Restructuring
- Executive Transition: Health Catalyst announced that Ben Albert will become the new CEO effective February 12, which aims to expedite the succession planning for retiring CEO Dan Burton, highlighting the company's commitment to leadership stability.
- Board Restructuring: The company is reducing its board size ahead of the 2026 Annual Meeting, with the departure of three directors leading to a total of five members, which may impact governance structure and decision-making efficiency.
- Historical Context: Ben Albert joined Health Catalyst in 2025 during the acquisition of Upfront Healthcare Services and became president and COO in 2022, indicating the company's preference for internal promotion to maintain management continuity.
- Future Outlook: With Dan Burton planning to retire in 2026, Albert's appointment not only accelerates succession planning but may also bring new strategic directions to the company, enhancing its competitive edge in the market.
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
- New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
- Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
- Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
- Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
- New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
- Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
- Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
- Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
Health Catalyst to Attend Upcoming Investor Conferences
Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.
Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.
Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.
Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
Health Catalyst (HCAT) Q3 Earnings Review: Analyzing Key Metrics Against Expectations
Health Catalyst Financial Performance: For Q3 2025, Health Catalyst reported revenue of $76.32 million, unchanged from the previous year, with an EPS of $0.06, down from $0.07 a year ago.
Earnings Surprises: The company's revenue exceeded the Zacks Consensus Estimate by 1.66%, and it delivered a 20% EPS surprise compared to the consensus estimate of $0.05.
Investor Insights: Key metrics beyond headline numbers are crucial for understanding a company's performance and guiding investors' decisions regarding stock price projections.
Stock Recommendations: Zacks Investment Research highlighted five stocks with potential for significant growth, emphasizing opportunities in lesser-known stocks that have previously shown substantial returns.
